These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 17028500)

  • 1. Ibandronate (boniva) offers new options for osteoporosis.
    Kessenich CR
    Nurse Pract; 2006 Oct; 31(10):64-6. PubMed ID: 17028500
    [No Abstract]   [Full Text] [Related]  

  • 2. Intravenous ibandronate (Boniva).
    Med Lett Drugs Ther; 2006 Aug 14-28; 48(1241-1242):68-9. PubMed ID: 16977282
    [No Abstract]   [Full Text] [Related]  

  • 3. Ibandronate: a review of its use in the management of postmenopausal osteoporosis.
    Frampton JE; Perry CM
    Drugs; 2008; 68(18):2683-707. PubMed ID: 19093707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Ibandronate (Bonviva) in the treatment of postmenopausal osteoporosis].
    Reginster JY
    Rev Med Liege; 2006 Nov; 61(11):783-6. PubMed ID: 17191748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates for osteoporosis.
    Favus MJ
    N Engl J Med; 2010 Nov; 363(21):2027-35. PubMed ID: 21083387
    [No Abstract]   [Full Text] [Related]  

  • 6. [The benefit from ibandronate in the treatment of postmenopausal osteoporosis].
    Málek Z
    Vnitr Lek; 2007 Oct; 53(10):1114-8. PubMed ID: 18072438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Ibandronate in the treatment of postmenopausal osteoporosis].
    Lakatos P
    Lege Artis Med; 2008 Oct; 18(10):657-61. PubMed ID: 19227607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of bisphosphonates in the management of postmenopausal osteoporosis.
    Papapoulos SE
    Ann N Y Acad Sci; 2011 Feb; 1218():15-32. PubMed ID: 20946579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ask the doctor. I'm looking for information on Prolia and Reclast as alternatives to Boniva.
    Robb-Nicholson C
    Harv Womens Health Watch; 2011 Nov; 19(3):8. PubMed ID: 22276325
    [No Abstract]   [Full Text] [Related]  

  • 10. Lasofoxifene: new drug. Osteoporosis: no better than raloxifene.
    Prescrire Int; 2009 Dec; 18(104):247. PubMed ID: 20020572
    [No Abstract]   [Full Text] [Related]  

  • 11. Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance.
    Boonen S; Vanderschueren D; Venken K; Milisen K; Delforge M; Haentjens P
    J Intern Med; 2008 Oct; 264(4):315-32. PubMed ID: 18823505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Does ibandronate (Bonviva) have an impact on non-vertebral fractures?].
    Kastelan D; Vlak T
    Reumatizam; 2007; 54(2):87-8. PubMed ID: 18351153
    [No Abstract]   [Full Text] [Related]  

  • 13. [Ibandronate once a month].
    Polk B
    Med Monatsschr Pharm; 2006 Jan; 29(1):36-7. PubMed ID: 16463553
    [No Abstract]   [Full Text] [Related]  

  • 14. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
    Pyon EY
    Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study.
    Eisman JA; Civitelli R; Adami S; Czerwinski E; Recknor C; Prince R; Reginster JY; Zaidi M; Felsenberg D; Hughes C; Mairon N; Masanauskaite D; Reid DM; Delmas PD; Recker RR
    J Rheumatol; 2008 Mar; 35(3):488-97. PubMed ID: 18260172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New bone density conservation agents for osteoporosis under research and development: Minodronic acid].
    Takata S
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():417-20. PubMed ID: 18161142
    [No Abstract]   [Full Text] [Related]  

  • 17. [Impacts on bone mineral density].
    Kurth A
    Orthopade; 2014 Feb; 43(2):182. PubMed ID: 24693554
    [No Abstract]   [Full Text] [Related]  

  • 18. Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis.
    Felsenberg D; Miller P; Armbrecht G; Wilson K; Schimmer RC; Papapoulos SE
    Bone; 2005 Nov; 37(5):651-4. PubMed ID: 16126016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progression of efficacy with ibandronate: a paradigm for the development of new bisphosphonates.
    Zaidi M; Epstein S; Harris ST; Kohles JD; Chesnut CH
    Ann N Y Acad Sci; 2007 Nov; 1117():273-82. PubMed ID: 18056047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
    Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
    J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.